Neumora Therapeutics, Inc. (NMRA)

Market Cap	610.08M +95.7%
Revenue (ttm)	n/a
Net Income	-236.30M
EPS	-1.46
Shares Out	169.94M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,347,503
Open	3.500
Previous Close	3.540
Day's Range	3.410 - 3.650
52-Week Range	0.611 - 3.650
Beta	3.25
Analysts	Buy
Price Target	8.00 (+122.84%)
Earnings Date	Mar 3, 2026

About NMRA

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease. In a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 15, 2023
• Employees: 95
• Stock Exchange: NASDAQ
• Ticker Symbol: NMRA
• Website: https://www.neumoratx.com

Analyst Summary

According to 10 analysts, the average rating for NMRA stock is "Buy." The 12-month stock price target is $8.0, which is an increase of 122.84% from the latest price.

Price Target

$8.0

(122.84% upside)

Analyst Consensus: Buy